You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT JAMA
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 284 No. 20, November 22, 2000 TABLE OF CONTENTS
  JAMA
  •  Online Features
  Original Contribution
 This Article
 •Full text
 •PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Citing articles on ISI (115)
 •Contact me when this article is cited
 Related Content
 •Related articles
 •Similar articles in JAMA
 Topic Collections
 •Neurology
 •Headache
 •Migraine
 •Randomized Controlled Trial
 •Adverse Effects
 •Alert me on articles by topic

Stratified Care vs Step Care Strategies for Migraine

The Disability in Strategies of Care (DISC) Study:

A Randomized Trial

Richard B. Lipton, MD; Walter F. Stewart, PhD, MPH; Andrew M. Stone, MSc; Miguel J. A. Láinez, MD; James P. C. Sawyer, MB, ChB

JAMA. 2000;284:2599-2605.

Context  Various guidelines recommend different strategies for selecting and sequencing acute treatments for migraine. In step care, treatment is escalated after first-line medications fail. In stratified care, initial treatment is based on measurement of the severity of illness or other factors. These strategies for migraine have not been rigorously evaluated.

Objective  To compare the clinical benefits of 3 strategies: stratified care, step care within attacks, and step care across attacks, among patients with migraine.

Design and Setting  Randomized, controlled, parallel-group clinical trial conducted by the Disability in Strategies Study group from December 1997 to March 1999 in 88 clinical centers in 13 countries.

Patients  A total of 835 adult migraine patients with a Migraine Disability Assessment Scale (MIDAS) grade of II, III, or IV were analyzed as the efficacy population; the safety analysis included 930 patients.

Interventions  Patients were randomly assigned to receive (1) stratified care (n = 279), in which patients with MIDAS grade II treated up to 6 attacks with aspirin, 800 to 1000 mg, plus metoclopramide, 10 mg, and patients with MIDAS grade III and IV treated up to 6 attacks with zolmitriptan, 2.5 mg; (2) step care across attacks (n = 271), in which initial treatment was with aspirin, 800 to 1000 mg, plus metoclopramide, 10 mg. Patients not responding in at least 2 of the first 3 attacks switched to zolmitriptan, 2.5 mg, to treat the remaining 3 attacks; and (3) step care within attacks (n = 285), in which initial treatment for all attacks was with aspirin, 800 to 1000 mg, plus metoclopramide, 20 mg. Patients not responding to treatment after 2 hours in each attack escalated treatment to zolmitriptan, 2.5 mg.

Main Outcome Measures  Headache response, achieved if pain intensity was reduced from severe or moderate at baseline to mild or no pain at 2 hours; and disability time per treated attack at 4 hours for all 6 attacks, compared among the 3 groups.

Results  Headache response at 2 hours was significantly greater across 6 attacks in the stratified care treatment group (52.7%) than in either the step care across attacks group (40.6%; P<.001) or the step care within attacks group (36.4%; P<.001). Disability time (6 attacks) was significantly lower in the stratified care group (mean area under the curve [AUC], 185.0 mm · h) than in the step care across attacks group (mean AUC, 209.4 mm · h; P<.001) or the step care within attacks group (mean AUC, 199.7 mm · h; P<.001). The incidence of adverse events was higher in the stratified care group (321 events) vs both step care groups (159 events in across-attack group; 217 in within-attack group), although most events were of mild-to-moderate intensity.

Conclusion  Our results indicate that as a treatment strategy, stratified care provides significantly better clinical outcomes than step care strategies within or across attacks as measured by headache response and disability time.


Author Affiliations: Departments of Neurology, Epidemiology, and Social Medicine, Albert Einstein College of Medicine, Bronx, NY, and Innovative Medical Research Inc, Stamford, Conn (Dr Lipton); Department of Epidemiology, Johns Hopkins School of Public Health, and Innovative Medical Research Inc, Baltimore, Md (Dr Stewart); AstraZeneca, Macclesfield, Cheshire, England (Mr Stone and Dr Sawyer); and Hospital Clinico Universitario, Universidad de Valencia, Valencia, Spain (Dr Láinez).


RELATED ARTICLES

Toward Evidence-Based Management of Migraine
David B. Matchar, Douglas C. McCrory, and Rebecca N. Gray
JAMA. 2000;284(20):2640-2641.
EXTRACT | FULL TEXT  

November 22/29, 2000
JAMA. 2000;284(20):2657-2658.
EXTRACT | FULL TEXT  

Migraine Headache
JAMA. 2000;284(20):2672.
PDF  


THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Diagnosing and Managing Migraine Headache
Mueller
JAOA: Journal of the American Osteopathic Association 2007;107:ES10-ES16.
ABSTRACT | FULL TEXT  

Combination of Sumatriptan and Naproxen for Migraine Reply
Brandes et al.
JAMA 2007;298:1276-1277.
FULL TEXT  

Familial risk of migraine: Variation by proband age at onset and headache severity
Stewart et al.
Neurology 2006;66:344-348.
ABSTRACT | FULL TEXT  

Clinical trials studying pharmacotherapy and psychological treatments alone and together
Haythornthwaite
Neurology 2005;65:S20-S31.
ABSTRACT | FULL TEXT  

Clinical trials of acute treatments for migraine including multiple attack studies of pain, disability, and health-related quality of life
Lipton et al.
Neurology 2005;65:S50-S58.
ABSTRACT | FULL TEXT  

A trial of metoclopramide vs sumatriptan for the emergency department treatment of migraines
Brenner et al.
Neurology 2005;65:1339-1340.
FULL TEXT  

Pediatric Migraine: Recognition and Treatment
Hershey and Winner
JAOA: Journal of the American Osteopathic Association 2005;105:2S-8S.
ABSTRACT | FULL TEXT  

Association of interatrial shunts and migraine headaches: Impact of transcatheter closure
Azarbal et al.
J Am Coll Cardiol 2005;45:489-492.
ABSTRACT | FULL TEXT  

Prevalence and impact of migraine and probable migraine in a health plan
Patel et al.
Neurology 2004;63:1432-1438.
ABSTRACT | FULL TEXT  

Pharmacologic Management of Migraine
Dowson et al.
ANN INTERN MED 2004;140:W-26-W-26.
FULL TEXT  

Migraine throughout the life cycle: Treatment through the ages
Landy
Neurology 2004;62:S2-8.
ABSTRACT | FULL TEXT  

Treatment approaches to maximizing therapeutic response in migraine
Brandes
Neurology 2003;61:S21-26.
ABSTRACT | FULL TEXT  

Headache Assessment and Management
Kaniecki
JAMA 2003;289:1430-1433.
FULL TEXT  

MIGRAINE: DIAGNOSIS AND MANAGEMENT
Elrington
J. Neurol. Neurosurg. Psychiatry 2002;72:ii10-15.
FULL TEXT  

Migraine -- Current Understanding and Treatment
Goadsby et al.
NEJM 2002;346:257-270.
FULL TEXT  

PedMIDAS: Development of a questionnaire to assess disability of migraines in children
Hershey et al.
Neurology 2001;57:2034-2039.
ABSTRACT | FULL TEXT  

The role of headache-related disability in migraine management: Implications for headache treatment guidelines
Lipton and Silberstein
Neurology 2001;56:S35-S42.
ABSTRACT | FULL TEXT  

Treatment Strategies for Migraine Headache
Lohman et al.
JAMA 2001;285:1014-1015.
FULL TEXT  

Stratified Care Is Better Than Step Care for Treatment of Migraine
JWatch Neurology 2001;2001:2-2.
FULL TEXT  

An Evidence-Based Approach to Migraine Treatment
JWatch Women's Health 2001;2001:9-9.
FULL TEXT  

Aspirin Plus Metoclopramide vs. Zolmitriptan for Migraine
JWatch General 2001;2001:3-3.
FULL TEXT  

Toward Evidence-Based Management of Migraine
Matchar et al.
JAMA 2000;284:2640-2641.
FULL TEXT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 2000 American Medical Association. All Rights Reserved.